Stockscreener 앱 받기
7.28
8.17%
0.55
Eupraxia Pharmaceuticals Inc 주식(EPRX)의 최신 뉴스
Eupraxia Pharmaceuticals Stock Falls 4.12% as Investors Weigh Clinical Progress Against Biotech Development and Financing Risk - kalkine.ca
Eupraxia Slides as Biotech Traders Take Risk Off the Table — What Could Trigger the Next Move? - kalkine.ca
Eupraxia Pharmaceuticals Faces Fresh Downside Pressure as Clinical Execution Risk Clouds the EoE Story - kalkine.ca
Eupraxia Pharmaceuticals Inc. Common Stock (NASDAQ: EPRX) Stock Price, News & Analysis - kalkine.ca
Eupraxia (EPRX) Quarter in Focus: EPS Does Not Reach the Reported Estimate for This Review - vinanet.vn
Eupraxia Pharmaceuticals Market Sentiment - Benzinga France
What's Going On With Eupraxia Pharmaceuticals Inc Stock Wednesday? - Wealth Awesome
Eupraxia (Nasdaq: EPRX) lines up $300M in securities offerings - Stock Titan
Eupraxia Pharmaceuticals (EPRX) Edges Higher to $6.72 as Biotech Sector Holds SteadyEqual Weight ETF - Vinanet
Eupraxia Pharmaceuticals announces results from RESOLVE study analysis - TipRanks
Eupraxia Pharmaceuticals (EPRX) Holds Gains as Shares Trade Near $6.72MFI Overbought - vinanet.vn
Eupraxia Pharmaceuticals (EPRX) Advances 0.75% as Price Approaches Key ResistancePost-Earnings Moves - vinanet.vn
H.C. Wainwright Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Why Eupraxia Pharmaceuticals Inc stock is sliding today - Wealth Awesome
Eupraxia Pharmaceuticals (EPRX) holders report around 4–5% stakes in 13G/A - Stock Titan
Why Eupraxia Pharmaceuticals Inc stock is rising today - Wealth Awesome
Eupraxia Pharmaceuticals Inc EPRX Earnings Beat Estimates by 0.0% - Wealth Awesome
Eupraxia reports symptom improvements in EoE trial analysis - Investing.com
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia in Eosinophilic Esophagitis Patients - Investing News Network
Eupraxia Posts Strong Long-Term Symptom Gains in Phase 1b/2a EoE Trial for EP-104GI - TipRanks
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients - thecanadianpressnews.ca
Eupraxia reports symptom improvements in EoE trial analysis By Investing.com - Investing.com India
Eupraxia Pharmaceuticals (EPRX) shows durable EoE symptom relief in RESOLVE trial - Stock Titan
Eupraxia Pharmaceuticals Inc (TSX:EPRX) Shares Decline as Clinical Development Risks and Biotechnology Market Volatility Pressure Sentiment - kalkine.ca
Eupraxia's RESOLVE Cohorts 7-9: No Severe Swallowing Pain at Weeks 24 or 52 - Stock Titan
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Eupraxia Q2 EPS beats estimate despite wider net loss - scanx.trade
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Issues Earnings Results - MarketBeat
Eupraxia Deepens Investment in EP-104GI as New Data Strengthen EoE Prospects - TipRanks
Eupraxia Pharmaceuticals (NASDAQ: EPRX) widens loss to $27.1M while raising $58.6M - Stock Titan
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results - GlobeNewswire
Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High? - finance.yahoo.com
Will Eupraxia Pharmaceuticals Inc (EPRX) Beat Earnings Estimates in Its Next Report? - Wealth Awesome
Eupraxia Pharmaceuticals Inc (EPRX) Stock News Today - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Eupraxia Pharmaceuticals (NASDAQ: EPRX) sets up US$300M mixed securities shelf - Stock Titan
Eupraxia Pharmaceuticals (EPRX) Edges Lower to $6.48, Holding Between Support and ResistancePut Wall - dars.gov.et
Eupraxia Pharmaceuticals (EPRX) to Post Earnings on Tuesday - MarketBeat
Eupraxia Pharmaceuticals (EPRX) Consolidates Near $6.50 as Investors Await Clinical MilestonesUnusual Put Volume - Vinanet
Bloom Burton Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Eupraxia Pharmaceuticals (EPRX) Edges Higher: Modest Gain Amid Biotech Sector WatchFactor Rotation - dars.gov.et
276,000 Shares in Eupraxia Pharmaceuticals Inc. $EPRX Acquired by DV Trading LLC - MarketBeat
William Blair Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating - Moomoo
Ally Bridge Group NY LLC Raises Stock Holdings in Eupraxia Pharmaceuticals Inc. $EPRX - MarketBeat
Eupraxia Pharmaceuticals Inc (EPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rubric Capital Management LP Takes $5 Million Position in Eupraxia Pharmaceuticals Inc. $EPRX - MarketBeat
Eupraxia Pharmaceuticals Inc (EPRX) Institutional Confidence - TradingKey
Why Eupraxia Pharmaceuticals Inc stock plummeted yesterday - Wealth Awesome
EPRX|Eupraxia Pharmaceuticals Inc|Price:5.810|Chg%:-0.490 - TradingKey
Eupraxia Pharmaceuticals, Inc. Revenue Breakdown – TSX:EPRX - TradingView
Eupraxia Pharmaceuticals Inc (EPRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Eupraxia Pharmaceuticals (EPRX) Slides 7.78% – Support Test in SightHigh Volume Node - vinanet.vn
TradingKey - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Cash Flow - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
EPRX|Eupraxia Pharmaceuticals Inc|Price:5.955|Chg%:+0.145 - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Eupraxia Pharmaceuticals Inc. (EPRX.TO) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
EPRX|Eupraxia Pharmaceuticals Inc|Price:5.910|Chg%:-0.390 - TradingKey
Eupraxia Pharmaceuticals (EPRX) Holds Steady Near Support Amid Low VolumeBullish Percent Index - dars.gov.et
Eupraxia Pharmaceuticals (EPRX) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Eupraxia Pharmaceuticals (EPRX) Q3 2024 earnings summary - Quartr
Eupraxia Pharmaceuticals (EPRX) Bloom Burton & Co. Healthcare Investor Conference 2026 summary - Quartr
0.00%
3.22%
자본화:
|
볼륨(24시간):